Immunosuppression, cancer, and the long-term outcomes after liver transplantation: Can we do better?

Liver Transplantation

Volumn 16, Issue 7, 2010, Pages 809-811

  Abraham, James M ^a   Thompson, Julie A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; RAPAMYCIN; TACROLIMUS; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; CANCER RISK; DE NOVO MALIGNANCY; EDITORIAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LONG TERM CARE; NEOPLASM; PRIORITY JOURNAL; GRAFT REJECTION; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; METHODOLOGY; NOTE; RISK FACTOR;

CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MONITORING, IMMUNOLOGIC; NEOPLASMS; RISK FACTORS;

EID: 77954152196     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22114     Document Type: Editorial

References (17)

1. Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, et al. Long-term survival after liver transplantation in 4000 consecutive patients at a single center. Ann Surg 2000;232:490-500.
2. Weisner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998;66:493-499.
3. Busuttil RW, Lake JR. Role of tacrolimus in the evolution of liver transplantation. Transplantation 2004;77(Suppl):S44-S51. (Pubitemid 38668459)
4. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a metaanalysis. Am J Transplant 2006;6:1578-1585.
5. Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001;34:84-91.
6. Benlloch S, Berenguer M, Prieto M, Moreno R, San Juan F, Rayón M, et al. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant 2004;4:596-604.
7. Schnitzbaum AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010;10:190.
8. Watt KDS, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009;137:2010-2017.
9. Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients. J Pediatr Gastroenterol Nutr 2004;38:198-203.
10. Tjon ASW, Nicolaas JS, Kwekkeboom J, de Man RA, Kazemier G, Tilanus HW, et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl 2010;16:837-846.
11. Villamil F, Pollard S. C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective. Liver Transpl 2004;10:577-583.
12. Sanchez EQ, Marubashi S, Jung G, Levy MF, Goldstein RM, Molmenti EP, et al. De novo tumors after liver transplantation: a single-institution experience. Liver Transpl 2002;8:285-291.
13. Jain AB, Yee LD, Nalesnik MA, Youk A, Marsh G, Reyes J, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998;66:1193-1200.
14. Duvoux C. De novo tumours after liver transplantation in adults. What is the actual risk? J Hepatol 2001;34:161-164.
15. Jain A, Marcos A, Reyes J, Mazariagos G, Kashyap R, Eghtesad B, et al. Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile. Transplant Proc 2005;37:1207-1210.
16. Thompson J, Weisner R, Lake J. Are tacrolimus (TAC) vs. cyclosporine ME (CSA)-based immunosuppressive regimens associated with different risks of death due to malignancy in adult liver transplant recipients? [Abstract] Liver Transpl 2007;13:S222.
17. Sanchez W, Talwalkar JA, Gores GJ. Will all liver transplantation patients eventually die from cancer? J Hepatol 2006;44:13-38.